Lineage Cell Therapeutics Presents at H.C. Wainwright Annual Conference

Lineage Cell Therapeutics presented at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The presenter, Sara Nik, an Equity Research VP at H.C. Wainwright, introduced Brian, who presented on the company. The content of the presentation is not specified in the provided transcript.

Lineage Cell Therapeutics, Inc. (LCTX) has announced the commencement of a new islet cell transplant program targeting Type 1 Diabetes (T1D). This initiative aims to address the significant challenge of large-scale production of islet cells, a critical hurdle in the commercialization of islet cell therapy product candidates Lineage Cell Therapeutics, Inc. Initiates Cell Transplant Program in Type 1 Diabetes^[1]Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes^[2].

The company's primary goal is to establish a dynamic culturing system capable of supporting the entire production process, with an initial focus on manufacturing scale. This program builds upon Lineage's recent success in Good Manufacturing Practice (GMP) manufacturing and utilizes a proprietary cell line, the third of its kind generated at the company's in-house facility Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes^[2].

According to Brian M. Culley, CEO of Lineage Cell Therapeutics, "Recent and emerging evidence suggests that an islet cell transplant may provide a functional cure for some people with diabetes. However, the manufacturing process required to supply sufficient material for a meaningful portion of the addressable patient population remains unsolved." By leveraging its manufacturing capabilities, Lineage aims to produce doses in the hundreds of millions of cells per eligible patient, potentially transforming the landscape of T1D treatment Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes^[2].

The initial feasibility of this program is expected to be assessed with a modest investment, with the potential to apply any relevant insights or improvements to other transplant programs. If successful, Lineage believes this production modality could create a compelling product profile and provide options for licensing the technology to a partner or entering the diabetes field directly Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes^[2].

About Type 1 Diabetes (T1D)
Type 1 diabetes (T1D) is a chronic autoimmune condition where the immune system attacks and destroys insulin-producing beta cells in the pancreas. This leads to high blood glucose levels, which can cause serious health complications if not managed properly. Unlike type 2 diabetes, T1D is not caused by lifestyle factors and cannot be prevented. Management requires lifelong insulin therapy, careful monitoring of blood sugar, diet, and physical activity. According to Breakthrough T1D, there are more than 9.5 million people living with type 1 diabetes worldwide Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes^[2].